Centessa Pharmaceuticals (NASDAQ:CNTA) Given Buy Rating at Guggenheim

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “buy” rating reiterated by analysts at Guggenheim in a report issued on Monday,Benzinga reports.

Separately, TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Stock Up 6.7 %

Shares of Centessa Pharmaceuticals stock opened at $19.03 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals has a 52-week low of $7.38 and a 52-week high of $19.09. The company’s 50 day moving average price is $16.77 and its 200-day moving average price is $15.44. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -12.44 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities research analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 77,705 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $16.39, for a total value of $1,273,584.95. Following the sale, the general counsel now owns 125,785 shares in the company, valued at approximately $2,061,616.15. This represents a 38.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the transaction, the chief executive officer now owns 575,661 shares of the company’s stock, valued at $10,626,702.06. The trade was a 13.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 421,697 shares of company stock worth $7,211,475. Company insiders own 11.59% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its stake in Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares in the last quarter. Harbour Capital Advisors LLC purchased a new position in Centessa Pharmaceuticals in the third quarter worth about $259,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after buying an additional 6,785 shares during the last quarter. Finally, Atria Investments Inc increased its position in shares of Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after acquiring an additional 1,116 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.